Veterinary Office Use Compounding

Preparations Available for Office Stock

Prepared for Veterinarian Clients of Parkside Compounding Pharmacy

Legal Framework Summary

Compounding animal drugs for veterinary office use (non-patient-specific “office stock”) is tightly regulated under both federal and California law. The following is a concise overview to help you understand the boundaries within which Parkside Compounding Pharmacy can legally supply compounds.

Federal Law (FDA)

- **Animal Medicinal Drug Use Clarification Act (AMDUCA) / 21 CFR 530:** Compounding from finished FDA-approved, conditionally approved, or indexed drugs is generally permitted as extra-label use when no approved product is available in a suitable dosage form and concentration, a valid veterinarian-client-patient relationship (VCPR) exists, and other conditions are met.
- **Guidance for Industry (GFI) #256:** Compounding from bulk drug substances (APIs) creates unapproved new animal drugs. FDA exercises enforcement discretion only under limited circumstances. For office stock for nonfood-producing animals, the bulk substance must appear on FDA’s List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals (or be under review), and the product must be needed for urgent treatment to prevent suffering or death when a patient-specific prescription cannot be filled in time.
- **Under Review List:** While FDA evaluates nominated bulk drug substances, the agency generally intends to refrain from taking enforcement action when these substances are used to compound a finished drug in a state-licensed pharmacy or by a state-licensed veterinarian as described in the initial nomination.
- Additional requirements include proper labeling (including that the product is compounded and not FDA-approved), adverse event reporting, compliance with state law, and use of components meeting USP standards.

California Law

- **Board of Pharmacy (16 CCR § 1735.1 and related):** A pharmacy may furnish a reasonable quantity of a compounded preparation to a veterinary office that is sufficient for administration solely in the veterinarian’s office, or for furnishing of no more than a 14-day supply for an individual patient (as fairly estimated by the prescriber and documented on the purchase order submitted to the pharmacy). Bulk substances must comply with GFI #256.
- **Veterinary Medical Board:** Veterinarians may also compound in their own registered premises under separate regulations (BPC § 4826.5 and 16 CCR §§ 2090 et seq.), with requirements for policies, procedures, quality assurance, labeling, and beyond-use dating.

Important: This document lists compounds from the FDA office-stock list and selected commonly requested items currently under review. The full under-review list is extensive and available on the FDA website. Availability is subject to confirmation of the current FDA lists, proper documentation from the prescribing veterinarian, and pharmacy operational capacity. This is not legal advice. Regulations and lists change; consult the current FDA GFI #256, the FDA bulk substance lists, California Board of Pharmacy regulations, and qualified counsel for your specific situation.

Compounds Available for Veterinary Office Stock

The table below includes (1) preparations from bulk drug substances currently listed by the FDA for compounding office stock under GFI #256, and (2) selected compounds currently under FDA review for which the agency generally intends to refrain from enforcement action while evaluation is pending. Dosage forms for under-review items reflect typical nominations; confirm specifics with the pharmacy.

Bulk Drug Substance	Species	Dosage Form(s) & Strength	Status / Notes
Chloramphenicol	Horse	Oral suspension 15–500 mg/mL; Oral paste 100–500 mg/mL	Listed – No suitable FDA-approved dosage form/concentration
Cisapride	Cat	Capsules 2.5 & 5 mg; Oral suspension 5–10 mg/mL	Listed – No currently marketed FDA-approved product
Clopidogrel	Dog, Cat	Oral suspension 2.5–37.5 mg/mL; Capsules 2–40 mg; Tablets 75 mg	Listed – Practical strengths for small patients
Famciclovir	Cat	Oral suspension 25–250 mg/mL	Listed – Accurate dosing for kittens or cats unable to take tablets
Gabapentin	Dog, Cat	Oral suspension 50 mg/mL	Listed – No universally safe FDA-approved oral suspension
Methocarbamol	Dog, Cat	Oral suspension 30–250 mg/mL	Listed – No FDA-approved oral suspension
Metronidazole benzoate	Cat	Oral suspension 80 mg/mL	Listed – No FDA-approved metronidazole benzoate product
Mirtazapine	Dog, Cat	Capsules 0.5–3.75 mg	Listed – Strengths suitable for small dogs and cats
Potassium bromide	Dog	Oral solution 250 mg/mL	Listed – No FDA-approved oral solution
Prazosin	Dog, Cat	Chews/flavored 0.25–0.5 mg; Capsules 0.25–0.5 mg; Oral liquid/suspension 0.15–15 mg/mL	Listed – Strengths for small dogs and cats
Rifampin	Horse	Oral suspension 100 mg/mL	Listed – No FDA-approved oral suspension
Trazodone	Dog	Oral capsules 3–20 mg; Oral suspension 2.5–20 mg/mL	Listed – Strengths suitable for small dogs
Enrofloxacin	Ferrets, chinchillas, gerbils, guinea pigs, hamsters, mice, rats	Oral suspension 22–34 mg/mL	Listed – No suitable FDA-approved or indexed alternative
Metronidazole benzoate	Captive avian (non-food)	Oral suspension 50 mg/mL	Listed – Strength needed for small captive avian species
Acepromazine maleate	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review

Bulk Drug Substance	Species	Dosage Form(s) & Strength	Status / Notes
Aluminum hydroxide	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Atenolol	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Benazepril HCl	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Budesonide	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Chlorambucil	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Chlorpheniramine maleate	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Clindamycin HCl	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Cyclophosphamide	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Dantrolene sodium	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Desmopressin	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Diltiazem	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Doxycycline	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Enalapril maleate	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Fluconazole	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Fludrocortisone acetate	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Furosemide	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Ketoconazole	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Phenobarbital	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review

Bulk Drug Substance	Species	Dosage Form(s) & Strength	Status / Notes
Pimobendan	Dog	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Prednisolone	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Theophylline	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Ursodiol	Dog, Cat, Horse	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review
Zonisamide	Dog, Cat	Oral forms (as nominated)	Under Review – FDA intends to refrain from enforcement while under review

Notes

- Quantities are limited to those sufficient for in-office administration ***or*** a maximum 14-day supply per individual patient under California Board of Pharmacy rules.
- A valid purchase order or documentation from the veterinarian is required prior to furnishing, estimating the quantity needed. A faxed or phoned order is sufficient.
- These products are for nonfood-producing animals only. Food-producing animals have separate, stricter limitations.
- Patient-specific prescriptions (with documented clinical rationale when required) may allow additional compounding options beyond this office-stock list.
- Beyond-use dates are assigned in accordance with USP <795> and California requirements and are typically shorter than commercially manufactured products.

Parkside Compounding Pharmacy & Wellness Center

Document prepared October 2026. Lists based on FDA materials as of that date. Always verify current status on the FDA website.